Monopar Therapeutics Targets Mid-2026 NDA Submission for ALXN1840 in Neurologic Wilson Disease

Monopar Therapeutics is advancing toward a mid-2026 NDA submission for ALXN1840 (tiomolibdate choline, TMC) in neurologic Wilson disease, a move that will test FDA's appetite for rare neurological indications backed by Phase 3 randomized controlled data. For CMC and regulatory teams, the submission timeline compresses preparation windows considerably, particularly around chemistry, manufacturing, and controls documentation that must align with current FDA expectations for rare disease packages.

Phase 3 FoCus trial data presented at the American Academy of Neurology Annual Meeting in April 2026 showed greater neurologic benefit for ALXN1840 versus standard of care in patients with neurologic symptoms at baseline. The same dataset is scheduled for presentation at the European Academy of Neurology Congress in Geneva on June 28 and at the EASL Congress in Barcelona on May 29, broadening the clinical evidence footprint ahead of the FDA filing. The sequential conference strategy suggests Monopar is building a peer-reviewed record to support the NDA's clinical section.

Commercial readiness is already in motion. Susan Rodriguez, appointed Chief Commercial and Strategy Officer in March 2026, is leading pre-launch activities, a signal that regulatory and commercial workstreams are running in parallel rather than sequentially. For QA directors, that parallel track raises questions about how manufacturing scale-up and process validation timelines are being managed against the NDA submission date.

On the financial side, R&D expenditure rose to $3.49 million in Q1 2026 from $1.64 million in Q1 2025, driven primarily by increased contractor, consulting, and personnel costs. Cash, equivalents, and investments stood at $137.5 million as of March 31, 2026, with the company projecting runway through at least December 31, 2027. That runway covers regulatory and potential commercial activities for ALXN1840, continued MNPR-101 development, and internal R&D, providing a financial buffer should the NDA review extend into a standard 12-month PDUFA cycle.

The mid-2026 NDA submission, if filed as planned, will set the clock on FDA's review timeline and determine whether ALXN1840 reaches the market within the company's current funding horizon.

Source: Monopar Therapeutics Inc. via GlobeNewswire, May 14, 2026.